A Pilot Study of In-lab Dynamic Standing in Parkinson's Disease

NCT07543861 | Recruiting Phase 1 FDA Device

• 1 other identifier: HUM00280455
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

This research is studying the use of a new type of standing desk in a small number of people to learn about the user experience for people with Parkinson's disease. 12 4-hour sessions will be performed to test the primary hypothesis that dynamic standing improves gait function compared to static standing and control sitting. This study has 2 phases. Phase 1 will be an open-label study and Phase 2 will be an in-lab randomized controlled trial pilot study. This is phase 1 of the study.

Conditions

Parkinson Disease

Outcome Measures

Primary Outcomes (5)

• Gait Speed

  Gait speed will be measured during an 8.5-meter forward walking task measured in meters per second.

  Baseline and post-intervention (up to 6 weeks).

• Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III

  Clinical assessment that measures motor symptoms in Parkinson's Disease. Higher scores indicates more severe symptoms. Scores range from 0-132.

  Baseline and post-intervention (up to 6 weeks).

• Montreal Cognitive Assessment

  Clinical assessment that measures cognition. Higher scores indicate better cognition. Scores range from 0-30.

  Baseline and post-intervention (up to 6 weeks).

• Timed Up and Go

  Clinical assessment that measures the time it takes for a participant to stand from a chair, walk 3 meters, turn around, walk back to the chair and sit back down. Higher time indicates increased motor impairment.

  Baseline and post-intervention (up to 6 weeks).

• 5 Times Sit to Stand

  Clinical assessment that measures the time it takes for a participant to sit and stand five times. Higher time indicates increased motor impairment.

  Baseline and post-intervention (up to 6 weeks).

Study Arms (1)

Dynamic Standing Desk in People with Parkinsons

EXPERIMENTAL

Up to 12 4-hour sessions with the dynamic standing desk completed in the span of 6 weeks.

Device: Dynamic Standing Desk

Interventions

Dynamic Standing Desk DEVICE

Participants will stand at the desk for 4 hours per session. During each session, the desk will move to prompt the participant to take small steps. Participants will take breaks as needed. Each participant will complete up to 12 sessions in the span of 6 weeks.

Dynamic Standing Desk in People with Parkinsons

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of Parkinson's Disease

You may not qualify if:

• Inability to stand or walk without an assistive device
• History of symptoms in stance that preclude safe and comfortable participation, such as dizziness and lightheadedness, orthostasis, severe symptomatic leg or back musculoskeletal pain, or medication side effects
• Any other history of medical or psychiatric comorbidity, precluding safe participation in the project.
• History of symptomatic cardiovascular or pulmonary disease
• History of active rheumatic arthritis
• History of stroke or other neurologic conditions with significant residual sensorimotor deficits
• History of disabling chronic pain syndrome requiring narcotic analgesics
• Evidence of dementia (Mini Mental State Exam (or Montreal Cognitive Assessment test) \<24 and significant impairment in activities of daily living)
• Venous ulcerative stasis or severe varicosities.
• Pregnancy as determined by urine pregnancy test prior to DXA procedure in women of childbearing potential.

Sponsors & Collaborators

• University of Michigan: lead

Study Sites (1)

Domino's Farms

Ann Arbor, Michigan, 48105, United States

RECRUITING

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Officials

• Chatkaew Pongmala, PhD

  University of Michigan

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Miriam Van Emde Boas, DPT

CONTACT

734-936-1174; bohnenmi@med.umich.edu

Chatkaew Pongmala, PhD

CONTACT

734-936-0111; pchatkae@med.umich.edu

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Research Investigator

Study Record Dates

• First Submitted: April 7, 2026
• First Posted: April 22, 2026
• Study Start: April 1, 2026
• Primary Completion (Estimated): March 1, 2027
• Study Completion (Estimated): March 1, 2027
• Last Updated: April 22, 2026

Record last verified: 2026-04

Locations

US (1)